WFWenhuan Feng

Wenhuan Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenhuan Feng has a total of 102 co-authors. Here are the top co-authors by number of shared publications:

  • Dalong Zhu

    Department of Endocrinology, Nanjing Drum Tower Hospital, affiliated with Nanjing University School of Medicine, Nanjing, China

    11 shared publications
  • Yan Bi

    Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine

    10 shared publications
  • Dalong Zhu

    Branch of national clinical research center for metabolic diseases

    4 shared publications
  • Wenjuan Tang

    Branch of National Clinical Research Center for Metabolic Diseases, Nanjing, China

    4 shared publications
  • Xinyue Xiang

    Department of Endocrinology, Endocrine and Metabolic Disease Medical Center, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China

    4 shared publications
  • Xuehui Chu

    Department of General Surgery, Drum Tower Hospital Affiliated to Nanjing Medical University, Nanjing, China

    4 shared publications

Latest Publications

  • Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery

    by Yuqin Ouyang, Wanying Zhong, Lijun Chen, Wenjuan Tang, Xiaodi Cao, Xuehui Chu, Dalong Zhu, Wenhuan Feng

    To determine the optimal timing for initiating liraglutide in patients with persistent obesity (BMI ≥ 28 kg/m² in China) six months after metabolic and bariatric surgery, a key gap in postoperative weight management. In this prospective study, 100 patients were allocated to receive liraglutide (3.0 mg/day) starting at 6 (LG-6), 9 (LG-9), or 12 (LG-12) months post-surgery, or standard care without liraglutide (n = 25 each). The primary endpoint was percent total weight loss (%TWL) at 18 months. Secondary outcomes included changes in body composition and remission of obesity-related comorbidities. All three liraglutide groups showed greater %TWL (LG-6 16.3 ± 5.7%, LG-9 13.7 ± 5.3%, LG-12 12.6 ± 6.0%) compared with controls (5.3 ± 5.2%; P < 0.05). Higher proportions of patients in liraglutide groups achieved BMI < 28 kg/m² (LG-6 40%, LG-9 52%, LG-12 36%) and ≥ 15% TWL (64%, 32%, 28%) versus controls (16%, 4%; P < 0.05). The LG-6 group showed the highest proportion reaching ≥ 20% TWL (24% vs. 0% in controls; P < 0.05). Reductions in fat mass and alanine transaminase, preservation of muscle mass, and remission of metabolic dysfunction-associated steatotic liver disease and hyperuricaemia were observed in association with liraglutide treatment. Early liraglutide initiation, particularly at six months post-surgery, was linked to greater weight loss and more favourable metabolic profiles compared with standard care. These findings suggest that timely pharmacotherapy may be associated with improved long-term weight management outcomes, though causality remains to be established.

  • Open Access

    Metabolic and bariatric surgery in mild obesity: mid-term outcomes and safety in an Asian population

    by Wanying Zhong, Lijun Chen, Yuanhao Huang, Dalong Zhu, Wenjuan Tang, Yuqin Ouyang, Xuehui Chu, Wenhuan Feng

    Background: Metabolic and bariatric surgery (MBS) is an established treatment for severe obesity, but its role in Asian patients with mild obesity (body mass index [BMI] 27.5-32.5 kg/m²) remains controversial due to limited mid-term evidence. This study evaluated the ≥3-year outcomes of MBS in this population compared with patients with BMI ≥32.5 kg/m². Objective: To evaluate the mid-term (≥3 years) efficacy and safety of MBS in Asian patients with mild obesity, compared with those with BMI ≥MIhe kg/m². Methods: In this retrospective cohort study, 26 patients with mild obesity and 76 matched patients with higher BMI underwent MBS between 2013 and 2020. Outcomes included percent total weight loss (%TWL), metabolic control, remission of obesity-related comorbidities, and postoperative complications. The primary composite endpoint was defined as glycated hemoglobin P < 0.05). Despite this, the rate of achieving the composite metabolic endpoint was comparable (30.7% vs 27.6%, P = 0.76). Both groups demonstrated sustained improvements in glycemic control, lipid profile, blood pressure, and insulin resistance. Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly in both groups (all P < 0.05). Notably, a substantially greater proportion of patients in the obesity group achieved normalization of body weight (BMI <24 kg/m²). Complication rates were low and comparable. Conclusion: In Asian patients, MBS appears safe and provides durable metabolic benefits across BMI categories. Despite losing less weight, those with mild obesity achieved similar cardiometabolic improvements and were more likely to reach a normal BMI. These findings are preliminary. Future research should prioritize large, multicenter studies focusing on the BMI 27.5–30 kg/m² subgroup without advanced metabolic disease, randomized trials comparing surgery with current pharmacotherapies, and long-term studies tracking hard cardiovascular endpoints.

  • Cognitive Improvement Following Bariatric Surgery is Associated with Enhanced Hippocampal Activation and Reduction in Visceral and Ectopic Fat Deposition

    by Yanjie Duan, Wenhuan Feng, Xitai Sun, Bing Zhang, Zhou Zhang, Yingwen Miao, Tianyu Wu, Wen Zhang, Wenhui Zhu, Xuewei Tong, et al.

    Background Evidence has demonstrated that patients with obesity exhibited cognitive impairment and cerebral damage. Bariatric surgery is an effective intervention for obesity and is associated with cognitive improvement. However, the underlying mechanisms by which bariatric surgery improves cognitive function remain unclear. This study aimed to evaluate cognitive alterations in patients with obesity before and after bariatric surgery, and to further explore the associations among fat reduction, cognitive alterations, and underlying cerebral changes. Methods We conducted an exploratory study on 23 patients with obesity who underwent bariatric surgery. These patients received anthropometric measurements, detailed cognitive assessments, and functional magnetic resonance imaging (fMRI) scans at baseline and 12 months post-surgery to evaluate neuroimaging and cognitive changes. Results Compared to baseline, patients with obesity exhibited significant improvements in immediate and delayed memory following bariatric surgery. fMRI scans also revealed increased left hippocampal volume and enhanced right hippocampal activation in patients with obesity postoperatively. Furthermore, these improvements in cognitive function and hippocampal activation were associated with reductions in visceral fat (β = -0.122, 95% bootstrap CI: -0.210, -0.030) and hepatic steatosis (β = -0.147, 95% bootstrap CI: -0.266, -0.053) in the mediation analysis. Conclusion This study showed that bariatric surgery significantly reduced fat deposition and improved cognitive function in patients with obesity. Importantly, the improvement in brain functional activation played a key role in alleviating cognitive impairment, underscoring its vital importance in cognitive health.


  • Open Access

    Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity

    by Yuqin Ouyang, Xinyue Xiang, Xinyun Hu, Xuehui Chu, Wenjuan Tang, Wenhuan Feng

    Background: Liraglutide effectively manages mild obesity, but individual weight loss outcomes vary significantly. We aimed to identify clinical predictors influencing differential treatment responses in patients with mild obesity.Methods: A retrospective analysis was conducted on 64 adults (BMI 28–32.5 kg/m²) undergoing a 12-week liraglutide intervention. Participants were categorized based on therapeutic success: those achieving composite endpoints (≥5% total weight loss [TWL] and BMI normalization to <28 kg/m²) versus suboptimal responders. Comprehensive biometric and biochemical assessments were performed, and multivariate predictive modeling was applied.Results: Responders (n=37, 75.7% female) showed significantly better metabolic outcomes than non-responders (n=27, 77.8% female), with notable differences in %TWL (11.0 ± 3.6% vs 4.2 ± 2.6%), total weight loss (9.04 ± 3.32 kg vs 3.55 ± 2.20 kg), and BMI reduction (3.3 ± 1.1 vs 1.4 ± 0.9 kg/m²) (all p’s <.01). Responders also demonstrated improved glucolipid metabolism, and reduced metabolic-associated fatty liver disease (p <.05). Regression analysis identified a history metabolic surgery (MS) and a baseline BMI ≥30.5 kg/m² as significant negative predictors of success. Adjusted odds ratios indicated strong inverse associations, with MS history showing an OR of 6.78 (95% CI: 1.95–23.61; p <.01) and elevated BMI (≥30.5 kg/m²) yielding an OR of 4.79 (95% CI: 1.46–15.71; p <.01).Conclusion: A history of MS significantly affects liraglutide’s responsiveness in patients with mild obesity, emphasizing the need for personalized therapeutic strategies in post-surgical patients. These findings highlight the importance of a comprehensive medical history in guiding obesity pharmacotherapy.


  • Open Access

    Impaired sensitivity to thyroid hormone is associated with developing non-alcoholic fatty liver disease in euthyroid diabetic subjects

    by Xiaowen Zhang, Jie Liu, Qian Wang, Chen Han, Yu Yan, Xinyue Xiang, Shanmei Shen, Wenhuan Feng

    Background and aims: Acquired resistance to thyroid hormone appears to exist in the general population. We aimed to evaluate the association between indices of thyroid hormone sensitivity and non-alcoholic fatty liver disease (NAFLD), and made stratified analyses by diabetic status.Methods: We included 26,413 participants from a health screening program and 8,246 hospitalized patients with type 2 diabetes. Thyroid Feedback Quantile-based Index (TFQI), thyroid stimulating hormone index (TSHI) and thyrotroph thyroxine resistance index (TT4RI) were calculated. Advanced fibrosis risk was determined using the FIB-4 score. Multivariate logistic regression analysis was performed.Results: TFQI was associated with an increased risk of NAFLD in patients with diabetes (fourth quartile vs. first quartile: odds ratio [OR]=1.39 and 1.82 in hospitalized and non-hospitalized patients, respectively, both P<0.001) but not non-diabetic participants (OR=0.94, P=0.40). Further adjustment for the homeostasis model assessment of insulin resistance generated similar findings in diabetes (OR=1.27, P=0.025). The TFQI-associated NAFLD risk increase in diabetic patients was confined to NAFLD with low probability of advanced fibrosis (OR 1.42, P=0.001), but not those with intermediate-to-high probability (OR=0.86, P=0.23). Also, TFQI was associated with a significantly lower risk for advanced fibrosis in the diabetic at-risk patients (OR=0.62, P=0.005) but not those non-diabetic at-risk participants, independent of the presence of NAFLD. The association was less significant for TT4RI and TSHI.Conclusions: Impaired sensitivity to thyroid hormone was associated with an increased risk of developing NAFLD but a reduced risk of advanced fibrosis limited to diabetic individuals. Our findings suggest stratified studies of NAFLD based on diabetic status are needed in the future.


  • Open Access

    The Efficacy and Safety of Liraglutide in Patients Remaining Obese 6 Months after Metabolic Surgery

    by Yuanyuan Shen, Yuanhao Huang, Yuqin Ouyang, Xinyue Xiang, Xuehui Chu, Bingqing Zhang, Tao Han, Wenjuan Tang, Wenhuan Feng

    Introduction The safety and efficacy of liraglutide as a weight loss intervention in individuals who remain obese within 1 year post-metabolic surgery remain unclear. This study aimed to evaluate the effects and safety of liraglutide (1.8 mg) in patients with persistent obesity at 6 months postoperatively. Methods This retrospective cohort study included 61 patients who remained obese (body mass index [BMI] ≥ 28.0 kg/m2) at 6 months postoperatively. Among these patients, 27 were treated with 1.8 mg of liraglutide for 12 weeks, whereas 34 served as controls. The primary endpoint was the change in total weight loss (%TWL) after 24 weeks. Changes in weight, BMI, complications, and adverse events were also assessed. Results The liraglutide group showed a greater reduction in %TWL than the control group (11.6% ± 1.1% vs. 4.9% ± 1.0%), with an estimated treatment difference of 6.6% (95% confidence interval [CI], 3.7–9.6%, P < 0.01). The adjusted mean differences in the reduction of weight and BMI between the liraglutide and control groups were − 6.2 kg (95% CI − 8.9 to − 3.4, P < 0.01) and − 3.0 kg/m2 (95% CI − 4.2 to − 1.7, P < 0.01), respectively. The liraglutide group exhibited increased rates of remission in non-alcoholic fatty liver disease and hypertension. No serious adverse reactions were observed. Conclusions For patients who remained obese at 6 months postoperatively, 12-week liraglutide treatment resulted in increased weight loss, improved metabolic control, and high rate of remission for obesity-related metabolic diseases after 24 weeks. Earlier and more timely adjuvant weight loss medication intervention based on BMI within 1 year postoperatively may enhance weight loss after metabolic surgery. Graphical abstract available for this article. Graphical Abstract


  • Metabolic surgery results in greater metabolic benefits in patients who achieve healthy weight

    by Yuanyuan Shen, Bingqing Zhang, Xinyun Hu, Ningjing Zhang, Yuanhao Huang, Tao Han, Xitai Sun, Xinyue Xiang, Yan Bi, Wenjuan Tang, et al.


  • Open Access

    Weight loss and metabolic benefits of bariatric surgery in China: A multicenter study

    by Wenhuan Feng, Zhiming Zhu, Xiaoying Li, Zhiguang Zhou, Shen Qu, Xitai Sun, Dalong Zhu

    Background: This retrospective multicenter study evaluated the efficacy and safety of bariatric surgery in Chinese patients with obesity.Methods: Patients with obesity who underwent laparoscopic sleeve gastrectomy or laparoscopic Roux‐en‐Y gastric bypass and completed a 12‐month follow‐up between February 2011 and November 2019 were enrolled. Weight loss, glycemic and metabolic control, insulin resistance, cardiovascular risk, and surgery‐related complications at 12 months were analyzed.Results: We enrolled 356 patients aged 34.3 ± 0.6 years with a mean body mass index of 39.4 ± 0.4 kg/m2. Successful weight loss occurred in 54.6%, 86.8%, and 92.7% of patients at 3, 6, and 12 months, respectively, with no difference in percent excess weight loss between the laparoscopic sleeve gastrectomy and laparoscopic Roux‐en‐Y gastric bypass surgery groups. The average percentage of total weight loss was 29.5% ± 0.6% at 12 months; 99.4%, 86.8%, and 43.5% of patients achieved at least 10%, 20%, and 30% weight loss, respectively, at 12 months. Significant improvements in metabolic indices, insulin resistance, and inflammation biomarkers were observed at 12 months.Conclusions: Bariatric surgery resulted in successful weight loss and improved metabolic control, insulin resistance, and cardiovascular risk in Chinese patients with obesity. Both laparoscopic sleeve gastrectomy and laparoscopic Roux‐en‐Y gastric bypass are suitable approaches for such patients.


  • Th1 bias of liver mucosal‐associated invariant T cells promotes hepatic gluconeogenesis in type 2 diabetes mellitus

    by Wenjuan Tang, Kang Ge, Lei Shen, Hongdong Wang, Wenhuan Feng, Xitai Sun, Xuehui Chu, Dalong Zhu, Hongli Yin, Yan Bi

    Aims: It is acknowledged that aberrant liver immunity contributes to the development of type 2 diabetes mellitus (T2DM). Mucosal‐associated invariant T (MAIT) cells, an innate‐like T‐cell subset, are enriched in the human liver. Nevertheless, the characterisation and potential role of hepatic MAIT cells in T2DM remain unclear.Materials and methods: Fourteen newly diagnosed T2DM subjects and 15 controls received liver biopsy. The frequency and cytokine production of MAIT cells were analysed by flow cytometry. The expression of genes involved in glucose metabolism was determined in HepG2 cells co‐cultured with hepatic MAIT cells.Results: Compared with controls, hepatic MAIT cell frequency was significantly increased in T2DM patients (24.66% vs. 14.61%, p = 0.001). There were more MAIT cells producing interferon‐γ (IFN‐γ, 60.49% vs. 33.33%, p = 0.021) and tumour necrosis factor‐α (TNF‐α, 46.84% vs. 5.91%, p = 0.021) in T2DM than in controls, whereas their production of interleukin 17 (IL‐17) was comparable (15.25% vs. 4.55%, p = 0.054). Notably, an IFN‐γ+TNF‐α+IL‐17+/−producing MAIT cell subset was focussed, which showed an elevated proportion in T2DM (42.66% vs. 5.85%, p = 0.021) and positively correlated with plasma glucose levels. A co‐culture experiment further indicated that hepatic MAIT cells from T2DM upregulated the gene expression of pyruvate carboxylase, a key molecule involved in gluconeogenesis, in HepG2 cells, and this response was blocked with neutralising antibodies against IFN‐γ and TNF‐α.Conclusions: Our data implicate an increased Th1‐like MAIT cell subset in the liver of newly diagnosed T2DM subjects, which induces hyperglycaemia by promoting hepatic gluconeogenesis. It provides novel insights into the immune regulation of metabolic homoeostasis.Clinical trial registration number: NCT03296605 (registered at www.clinicaltrials.gov on 12 October 2018).


  • Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity

    by Yuzhe Fu, Ningjing Zhang, Wenjuan Tang, Yan Bi, Dalong Zhu, Xuehui Chu, Xiaodong Shan, Yuanyuan Shen, Xitai Sun, Wenhuan Feng

    Background and purpose The association between the severity of obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) in patients with obesity remains unclear. We conducted this study to determine the effects of OSA on the severity of NAFLD in individuals with obesity and its link to the development of non-alcoholic steatohepatitis (NASH). Methods Patients were subjected to standard polysomnography up to 1 week before undergoing bariatric surgery, during which liver biopsy specimens were obtained. The apnea–hypopnea index (AHI) obtained by polysomnography was used to determine the severity of OSA. Results In total, 183 patients with obesity and biopsy-confirmed NAFLD were included; 49 (27%) had NASH. Patients with NASH had higher AHIs (p = 0.014) and oxygen desaturation indices (p = 0.031), more frequent OSA (p = 0.001), and lower minimum oxygen saturation (p = 0.035). The severity of OSA was directly correlated with the NAFLD activity score (p < 0.001), NASH activity grade (p < 0.001), semi-quantitative indices of lobular inflammation (p = 0.001), and hepatocyte ballooning (p = 0.006). The odds ratios (95% confidence intervals) for NASH and severe NASH (activity grade ≥ 3) associated with moderate-to-severe OSA were 3.85 (1.35–10.94; p < 0.05) and 5.02 (1.66–15.18; p < 0.01), respectively, after adjusting for sex, age, body mass index, waist circumference, insulin resistance values, and metabolic syndrome. Conclusions Chronic intermittent hypoxia caused by OSA may aggravate NAFLD and lead to a higher risk of NASH in patients with obesity.